The FDA has approved Eli Lilly’s Cymbalta (duloxetine HCl) for the management of fibromyalgia, a chronic widespread pain disorder. The approval makes Cymbalta the first serotonin-norepinephrine reuptake inhibitor approved for reducing pain in patients with fibromyalgia.
Allergan said the FDA has approved Trivaris (triamcinolone acetonide injectable suspension), a synthetic glucocorticoid corticosteroid with anti-inflammatory action to treat sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.
